Alvotech

NasdaqGM:ALVO 주식 리포트

시가총액: US$1.2b

Alvotech 배당 및 자사주 매입

배당 기준 점검 0/6

Alvotech 배당금을 지급한 기록이 없습니다.

핵심 정보

n/a

배당 수익률

-6.7%

자사주 매입 수익률

총 주주 수익률-6.7%
미래 배당 수익률0%
배당 성장률n/a
다음 배당 지급일n/a
배당락일n/a
주당 배당금n/a
배당 성향n/a

최근 배당 및 자사주 매입 업데이트

업데이트 없음

Recent updates

내러티브 업데이트 • Jul 07

ALVO: Biosimilar Advances And Fresh Capital Raises Will Drive Future Upside

Analysts have revised their price target on Alvotech to $50.00, citing updated assumptions for revenue growth, profit margins, and a lower discount rate, which also leads to a reduced future P/E multiple in their models. What’s in the News for Alvotech Alvotech completed a series of capital raises, including a $125 million public offering and related transactions, with some analysts suggesting the stock may appear undervalued based on certain valuation measures, source: Alvotech stock offering coverage.
내러티브 업데이트 • Jun 23

ALVO: 2026 Guidance Balanced By Capital Raise And Regulatory Milestones

Analysts have adjusted their price target on Alvotech to $4.00. The updated view reflects slightly lower discount rate assumptions, a modestly higher revenue growth outlook and profit margin expectations, and a marginally lower future P/E multiple.
Seeking Alpha • Jun 08

Alvotech: Speculative 'Buy' Despite The FDA's CMC Requirements

Summary Alvotech remains a commercial-stage biosimilar company with real revenue, partners, and a growing global footprint. I believe its main upside potential lies with the resubmission of AVT05 and AVT06 after its recent manufacturing delays in the US. ALVO’s valuation has been punished by regulatory setbacks in its manufacturing facilities. So if those concerns are resolved, the stock could quickly re-rate higher. However, there are also substantial risks related to its cash burn and runway until we see ALVO’s optimistic guidance materialize later this year. In my view, ALVO is a viable speculative "Buy" for investors who believe ALVO will ultimately satisfy the FDA’s CMC requirements. Read the full article on Seeking Alpha
내러티브 업데이트 • Jun 06

ALVO: FDA Resubmissions And 2026 Biosimilar Launch Plan Will Drive Upside

Analysts have trimmed their average price target on Alvotech to about $13.83 from $14.00, linking the change to updated views on future P/E assumptions, as well as adjusted expectations for revenue growth and profit margins. Analyst Commentary Recent Street research on Alvotech points to a mixed but focused view on the stock, with several firms adjusting price targets and updating their assumptions around P/E, revenue growth, and margins.
내러티브 업데이트 • May 19

ALVO: 2026 Revenue Guidance And Pipeline Execution Will Drive Future Upside

Analysts have trimmed their price targets on Alvotech by $1 to $4. This reflects updated views on the company’s growth, profitability, discount rate, and future P/E assumptions.
내러티브 업데이트 • Apr 29

ALVO: Biosimilar Pipeline And Patent Resolutions Will Support Future Upside

Analysts have reduced their average price target on Alvotech to $46.50, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margins and future P/E following recent target cuts from several major banks. Analyst Commentary Recent Street research on Alvotech has centered on recalibrated price targets, with several banks updating their models for valuation drivers such as revenue growth assumptions, margin profiles and target P/E multiples.
내러티브 업데이트 • Apr 15

ALVO: Biosimilar Pipeline And Partnerships Will Shape Future Upside Potential

Analysts have reduced their price targets on Alvotech, with the consolidated fair value estimate moving from $5.00 to $4.00 as they factor in more moderate revenue growth, lower profit margin assumptions, a higher discount rate, and a higher future P/E multiple. Analyst Commentary Bearish analysts are aligning around a lower fair value for Alvotech, with recent price target revisions pointing to a more cautious stance on the stock.
내러티브 업데이트 • Mar 31

ALVO: Executing Biosimilar Pipeline And 2026 Revenue Plan Will Unlock Upside

Analysts have reset their view on Alvotech, trimming the average price target from about $22.17 to $14.00 as they factor in updated assumptions for growth, profitability and a higher future P/E, in line with recent target cuts from Deutsche Bank, Barclays and UBS. Analyst Commentary Recent Street research around the reset in the average price target to about $14.00 centers on how quickly Alvotech can execute on its pipeline and translate that into sustainable profitability, as well as what P/E multiple is appropriate given current visibility.
내러티브 업데이트 • Mar 17

ALVO: Biosimilar Pipeline Progress And Patent Resolutions Will Support Future Upside

Analysts have adjusted their price target for Alvotech to $64.74 per share. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E, while keeping the overall valuation level unchanged.
내러티브 업데이트 • Mar 03

ALVO: Patent Resolution And Biosimilar Progress Will Support Future Upside

Analysts have updated their price target on Alvotech to $64.74 from $82.94, reflecting revised assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News Alvotech reported positive top line pharmacokinetic results for AVT80, its biosimilar candidate to Entyvio (vedolizumab), with the PK study meeting all primary endpoints in healthy adults, while biosimilarity has not yet been established by regulators.
내러티브 업데이트 • Feb 17

ALVO: Biosimilar Progress And New Partnerships Will Shape Balanced Risk Outlook

Analysts have raised their price target on Alvotech to $5.00. This change is supported by slightly higher assumptions for revenue growth, profit margin and future P/E.
내러티브 업데이트 • Feb 03

ALVO: Rebased UBS View And Patent Resolution Will Support Future Upside

Narrative Update on Alvotech Analysts have reduced their price expectations for Alvotech, with one recent update moving a target to US$10 from US$13, along with lower fair value estimates and more conservative assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Even with lower headline price targets, some bullish analysts still see room for upside in Alvotech.
내러티브 업데이트 • Jan 20

ALVO: FDA Letters And Facility Remediation Will Guide Balanced Risk Outlook

Narrative Update on Alvotech The updated analyst price targets for Alvotech, which now cluster around US$8 to US$10 compared with prior views near US$13 to US$14, reflect analysts factoring in recent FDA complete response letters tied to inspection findings at the Reykjavik facility, while still recognizing the unchanged US$5 fair value estimate and broadly similar growth and margin assumptions in the model. Analyst Commentary Recent Street research on Alvotech points to a more cautious tone, with price targets now centered in the US$8 to US$10 range and at least one rating move to Hold after the complete response letter for AVT05 and related inspection findings at the Reykjavik facility.
내러티브 업데이트 • Jan 05

ALVO: FDA Setbacks And Manufacturing Fixes Will Shape Balanced Risk Profile

Analysts have trimmed their fair value estimate for Alvotech from US$14.00 to US$5.00. This reflects lower price targets on the stock after recent FDA-related setbacks and manufacturing inspection concerns highlighted in recent research updates.
내러티브 업데이트 • Dec 17

ALVO: Resolution Of FDA Inspection Issues Will Unlock Biosimilar Launch Upside

Analysts have reduced their average price target for Alvotech from about $26.40 to roughly $22.17 per share, citing FDA inspection related uncertainties around key biosimilar launches, as well as a series of recent target cuts and rating downgrades, as justification for a lower, though still constructive, valuation framework. Analyst Commentary Recent Street research reflects a more cautious stance on Alvotech, with several firms cutting price targets and one moving to the sidelines following regulatory setbacks tied to the company’s biosimilar pipeline.
내러티브 업데이트 • Dec 03

ALVO: Regulatory Resolution Of Manufacturing Issues Will Restore Confidence And Future Upside

Analysts have trimmed their price targets on Alvotech, with cuts of roughly $3 to $6 per share. The reductions reflect increased perceived regulatory risk after recent FDA feedback on key biosimilar programs.
분석 기사 • Nov 20

Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position

Even though Alvotech ( NASDAQ:ALVO ) posted strong earnings recently, the stock hasn't reacted in a large way. We...
내러티브 업데이트 • Nov 19

ALVO: Regulatory Progress Will Drive Renewed Confidence Amid Recent Downgrade

Alvotech's fair value price target saw a significant increase from $16.10 to $26.40, as analysts revised their outlook based on recent research reports and updated fundamentals. Analyst Commentary Recent analyst reports on Alvotech reflect a mix of optimism about the company's long-term potential and caution regarding recent regulatory and operational setbacks.
분석 기사 • Nov 09

Alvotech's (NASDAQ:ALVO) 31% Dip In Price Shows Sentiment Is Matching Revenues

Alvotech ( NASDAQ:ALVO ) shareholders that were waiting for something to happen have been dealt a blow with a 31% share...
분석 기사 • Nov 06

Analysts Just Slashed Their Alvotech (NASDAQ:ALVO) EPS Numbers

Market forces rained on the parade of Alvotech ( NASDAQ:ALVO ) shareholders today, when the analysts downgraded their...
내러티브 업데이트 • Nov 05

ALVO: Facility Improvements Will Drive Recovery Despite Recent Regulatory Setbacks

Alvotech’s analyst price target has decreased from $17.50 to $16.10 per share. This change reflects analyst concerns over FDA feedback and the resulting downgrades after a recent inspection of the company’s manufacturing facility.
분석 기사 • May 25

Alvotech (NASDAQ:ALVO) Held Back By Insufficient Growth Even After Shares Climb 29%

Those holding Alvotech ( NASDAQ:ALVO ) shares would be relieved that the share price has rebounded 29% in the last...
분석 기사 • May 15

Alvotech's (NASDAQ:ALVO) Promising Earnings May Rest On Soft Foundations

Unsurprisingly, Alvotech's ( NASDAQ:ALVO ) stock price was strong on the back of its healthy earnings report. However...
User avatar
새로운 내러티브 • May 05

Biosimilar Pipeline And R&D Capability Will Open New Markets

Upcoming biosimilar launches and strategic manufacturing expansions might drive substantial revenue and margin growth, leveraging lost biologic patents.
분석 기사 • Apr 08

Benign Growth For Alvotech (NASDAQ:ALVO) Underpins Stock's 25% Plummet

Unfortunately for some shareholders, the Alvotech ( NASDAQ:ALVO ) share price has dived 25% in the last thirty days...
Seeking Alpha • Nov 21

Alvotech's Position In The Coming Biosimilar Gold Rush

Summary Alvotech focuses on biosimilars, aiming to lower healthcare costs amid rising drug prices and regulatory pressure against price hikes. Alvotech's aggressive market expansion shows promise with significant revenue growth and strategic product rollouts, despite a leveraged balance sheet. A diverse pipeline targeting high-value biologics and recent regulatory milestones position Alvotech for significant market impact in the biosimilar sector. While facing risks like competition and partner dependency, Alvotech's strategic focus and operational scalability offer considerable growth potential for long-term investors. Read the full article on Seeking Alpha
Seeking Alpha • Aug 26

Alvotech: Steady Progress Offers A Good Chance Of Upside

Summary Alvotech offers exposure to the biosimilar industry at a cheaper price compared to other generic drug manufacturers. The company has successfully commercialized two biosimilar drugs - Stelara and Humira - with more in the pipeline. The company announced Q2 earnings on August 16th, with record revenues of $235.6 million and quarterly EBITDA of $102 million. With revenues of $600 million to $800 million promised in 2025, Alvotech stock stands a good chance of realising upside in the second half of 2024. Read the full article on Seeking Alpha
분석 기사 • May 28

Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts

Celebrations may be in order for Alvotech ( NASDAQ:ALVO ) shareholders, with the analysts delivering a significant...
Seeking Alpha • Apr 25

Alvotech: Consider Buying As Positive Q1 Earnings Release Likely

Summary Alvotech has received FDA approval for its biosimilar drugs Simlandi and Selarsdi, allowing the company to compete in the biosimilar market for Humira and Stelara. The company's stock price initially dropped after the FDA rejected Simlandi in 2023, but has since recovered. Alvotech's outlook for 2024 and 2025 is positive, with projected revenues of $300-$400 million and potential growth in the biosimilar market. Q1 2024 earnings will be announced on May 22 and have the potential to exceed Wall Street's expectations, in my view, setting the company on a long-term path to valuation growth, although significant headwinds remain in play. Read the full article on Seeking Alpha

지급의 안정성과 성장

배당 데이터 가져오는 중

안정적인 배당: 과거에 ALVO 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: ALVO 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

배당 수익률 vs 시장

Alvotech 배당 수익률 vs 시장
ALVO의 배당 수익률은 시장과 어떻게 비교되나요?
구분배당 수익률
회사 (ALVO)n/a
시장 하위 25% (US)1.3%
시장 상위 25% (US)4.1%
업계 평균 (Biotechs)2.1%
분석가 예측 (ALVO) (최대 3년)0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ALVO 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ALVO 의 배당 수익률을 평가할 수 없습니다.

주주 대상 이익 배당

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ALVO 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주 현금 배당

현금 흐름 범위: ALVO 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

높은 배당을 제공하는 우량 기업 찾기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/07/20 16:55
종가2026/07/20 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Alvotech는 8명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Glen SantangeloBarclays
Peter VerdultCitigroup Inc
Andrew BaumCitigroup Inc